alpha-玉红霉素 | 27267-69-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 萘并呋喃类
• 中文名称: alpha-玉红霉素
• 中文别名: 甲基7,8-二羟基-6-[2-(8-羟基-5,7-二甲氧基-4,9-二羰基-4,9-二氢萘并[2,3-b]呋喃-2-基)乙基]-1-羰基-1H-异色烯-3-羧酸酯
• 英文名称: α-rubromycin
• 英文别名: α-Rubromycin = Collinomycin；Collinomycin；methyl 7,8-dihydroxy-6-[2-(8-hydroxy-5,7-dimethoxy-4,9-dioxobenzo[f][1]benzofuran-2-yl)ethyl]-1-oxoisochromene-3-carboxylate
• CAS: 27267-69-2
• 化学式: C₂₇H₂₀O₁₂
• 分子量: 536.449
• InChiKey: LQNGOIZVRFNQLO-UHFFFAOYSA-N

物化性质

• 熔点：
  280-282°
• 沸点：
  533.53°C (rough estimate)
• 密度：
  1.3841 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  39
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  179
• 氢给体数：
  3
• 氢受体数：
  12

文献信息

• Carriers, Formulations, Methods For Formulating Unstable Active Agents For External Application And Uses Thereof
  申请人：Foamix Ltd.

  公开号：US20130189191A1

  公开（公告）日：2013-07-25

  The present disclosure teaches unique formulations for topical administration of tetracycline antibiotics, in which the tetracycline antibiotics remain stable.

  本公开教授了一种独特的四环素类抗生素外用给药配方，其中四环素类抗生素保持稳定。
• CARRIERS, FORMULATIONS, METHODS FOR FORMULATING UNSTABLE ACTIVE AGENTS FOR EXTERNAL APPLICATION AND USES THEREOF
  申请人：Tamarkin Dov

  公开号：US20100310476A1

  公开（公告）日：2010-12-09

  The present disclosure teaches unique formulations for topical administration of tetracycline antibiotics, in which the tetracycline antibiotics remain stable.

  本公开教授了独特的四环素类抗生素局部给药配方，其中四环素类抗生素保持稳定。
• Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
  申请人：Proteotech Inc.

  公开号：EP1808169A2

  公开（公告）日：2007-07-18

  Polyhydroxylated aromatic compounds, and compositions containing them, are useful for the treatment of amyloidosis, especially Alzheimer's disease, and for the treatment of diseases characterized by α-synuclein fibril formation, especially Lewy body disease and Parkinson's disease.

  多羟基芳香族化合物和含有它们的组合物可用于治疗淀粉样变性病，特别是阿尔茨海默病，以及治疗以α-突触核蛋白纤维形成为特征的疾病，特别是路易体病和帕金森病。
• Pharmaceutical compositions for treating ebola virus disease
  申请人：Vecht-Lifshitz Susan Eve

  公开号：US10369166B2

  公开（公告）日：2019-08-06

  The present invention provides compounds and pharmaceutical compositions adapted to reduce a load of an RNA virus by at least 50%, the virus causing a pathogenic disease in a mammalian subject, the compound adapted to inhibit the formation of S-adenosyl methionine (SAM) in the virus, the compound being a DOTIL inhibitor, wherein the compound has a molecular weight of less than 1000, and a therapeutic index (TI=LD.sub.50:ED.sub.50) greater than 30 in the mammalian subject.

  本发明提供的化合物和药物组合物适于将 RNA 病毒的载量减少至少 50%，该病毒在哺乳动物体内引起致病性疾病，该化合物适于抑制病毒中 S-腺苷蛋氨酸（SAM）的形成，该化合物是一种 DOTIL 抑制剂，其中该化合物的分子量小于 1000，在哺乳动物体内的治疗指数（TI=LD.sub.50:ED.sub.50）大于 30。
• Processes and host cells for genome, pathway, and biomolecular engineering
  申请人：enEvolv, Inc.

  公开号：US10370654B2

  公开（公告）日：2019-08-06

  The present disclosure provides compositions and methods for genomic engineering.

  本公开提供了基因组工程的组合物和方法。